Raising capital for an emerging biotech company is rarely easy. Tremendous time and effort goes into crafting the perfect story, determining the amount of capital you need to raise and what that money will be used for and reaching out to investors. It can be a long...

A well-known Catch-22 in the business world is known as the Permission Paradox — “You can’t get the job without experience, and you can’t get the experience without the job”¹. This dilemma is commonly encountered by life science business development...

When a company decides to seek a strategic development or commercial partner for an asset, the first inclination is often to identify the likely buyers and begin conversations about a potential deal. However, entering a deal process without first having a full...

Licensing and M&A deals are an essential part of the success, lifeblood and motivation for small biopharmaceutical companies. As large and specialty pharmaceutical and biotech companies continually strive for innovation, there are powerful financial incentives...

The approval of the referendum for the United Kingdom’s withdrawal from the European Union (“Brexit”) has cast a shadow of uncertainty on global financial markets. All industries, including biopharma, are scrambling to discern what the UK’s vote means for them....

Locust Walk Institute’s first course focused on financing transactions from idea to IPO was a success. On May 4th & 5th, biopharma executives joined experts from event sponsors Cooley and Locust Walk along with supporters PwC and MacDougall BioMedical...